People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| KSQ Therapeutics, Inc. | — | Pharmaceuticals | Series C | $80.6M | $2.8B | 2018 |
FRANK P. STEGMEIER, PH.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside FRANK P. STEGMEIER, PH.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alan L. Crane | 1 | 3 |
| David P. Meeker, M.D. | 1 | 2 |
| DAVID A. BERRY, M.D., PH.D. | 1 | 2 |
| JOHN P. TRZUPEK, PH.D. | 1 | 1 |
| RICHARD A. MOSCICKI, PH.D. | 1 | 1 |
| GEORGE L. GOLUMBESKI | 1 | 1 |
| JAMES L. GILBERT | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.